期刊文献+

心脏α_1肾上腺素能受体与心肌细胞凋亡 被引量:2

Cardiac alpha_1-adrenergic receptors and myocardial apoptosis
下载PDF
导出
摘要 α_1肾上腺素能受体(α_1-ARs)在心脏中占据的比例虽少,但对心脏正常功能的维持有至关重要的作用,可通过下游信号通路的多向性激活抑制心衰时的病理性心肌重构:促使心肌细胞适应性肥大、抑制心肌细胞凋亡、增加心肌收缩性、诱导缺血预适应.心脏α_1-ARs主要位于细胞核内,依赖"由内向外"的信号通路来发挥心肌保护作用.本综述为α_1-ARs在抑制心肌细胞凋亡中的研究进展. Cardiac alpha1-adrenergic receptors (α1-ARs) mediate important protective functions in the heart, although α1-ARs are only a small fraction of the total cardiac ARs. Cardiac α1-ARs activate pleiotropic downstream signaling to prevent pathologic remodeling in heart failure, and the mechanisms include activation of adaptive hypertrophy, prevention of myocardial apoptosis, augmentation of contractility, and induction of ischemic preconditioning. In the recent years, more and more studies showed that α1-ARs localize to the nucleus of cardiomyocytes and activate the “inside-out” signaling to cause cardioprotection. We summarize the recent progress of α1-ARs in preventing myocardial apoptosis.
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 北大核心 2016年第3期221-225,共5页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 国家自然科学基金项目(81372028) 广东省自然科学基金项目(S2011020005408)
关键词 Α1肾上腺素能受体 心肌细胞 凋亡 alpha1-adrenergic receptors cardiac apoptosis
  • 相关文献

参考文献32

  • 1JOHNSON J A, LIGGET'F S B. Cardiovascular pharma- cogenomics of adrenergic receptor signaling: clinical im- plications and future directions [ J ]. Clin Pharmacol T- her, 2011, 89(3) : 366 -378.
  • 2MICHEL M C. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dys- function: alpha-blockers in the treatment of male voiding dysfunction-how do they work and why do they differ in tolerability[J]. J Pharmacol Sci, 2010, 112(2) : 151 - 157.
  • 3SIMPSON P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic re- sponse[J]. J Clin Invest, 1983, 72(2) : 732 -738.
  • 4ANTIHYPERTENSIVE, LIPID-LOWERING TREAT- MENT TO PREVENT HEART ATTACK TRIAL COL- LABORATIVE RESEARCH GROUP. Diuretic versus c- blocker as first-step antihypertensive therapy final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) [ J ]. Hypertension, 2003, 42 (3) : 239 - 246.
  • 5COHN J N. The vasodilator-heart failure trials (V- HeFr). Mechanistic data from the VA cooperative stud- ies. Introduction[ J]. Circulation, 1993, 87 (6 Suppl) : VI1 - 4.
  • 6DHALIWAL A S, HABIB G, DESWAL A, et al. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure [J]. Am J Cardiol, 2009, 104(2) : 270 -275.
  • 7WU S C, O' CONNELL T D. Nuclear compartmentaliza- tion of alphal-adrenergic receptor signaling in adult cardi- ac myocytes[ J]. J Cardiovasc Pharmacol, 2015, 65 (2) : 91 - 100.
  • 8O'CONNELL T D, JENSEN B C, BAKER A J, et al. Cardiac alpha ( 1 ) -adrenergic receptors : novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance [ J]. Pharmacol Rev, 2014, 66 (1): 308-333.
  • 9JENSEN B C, O'CONNELL T D,SIMPSON P C. Alpha- l-adrenergie receptors in heart failure: the adaptive arm of the cardiac response to chronic eatecholamine stimula- tion[ J]. J Cardiovase Pharmaeol, 2014, 63 (4) : 291 - 301.
  • 10JENSEN B C, SWIGART P M, MONTGOMERY M D, et al. Functional alpha-lB adrenergic receptors on human epicardial coronary artery endothelial ceils [ J ]. Naunyn Schmiedebergs Arch Pharmacol, 2010, 382 (5/6) : 475 - 482.

同被引文献32

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部